Scipher Medicine, a precision immunology firm has acquired Philadelphia-based data, analytics, and software company CrossBridge with an aim to support its data and analytic capabilities.
With Scipher new data management and analytics capabilities, a more detailed and real-time understanding of patients’ treatment pathway is possible. SaaS value-based care platform bridges gaps between providers, payers, patients, and improves health outcomes. In addition, it also lowers the cost of care for autoimmune disease patients. The transaction has closed, and terms were not made public.
“There is a significant need to better understand how and when to apply various therapeutic and diagnostic interventions to improve the treatment pathway for patients,” said Scipher’s Chief Executive Officer Alif Saleh in a statement. “To date, we have not had a platform combining critical patient molecular, clinical and claims data as autoimmune diseases, including rheumatoid arthritis.